Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-IBusiness Wire • 03/09/21
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational ResultsBusiness Wire • 02/25/21
Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy PipelineBusiness Wire • 01/11/21
Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/21
Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesBusiness Wire • 12/14/20
Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon DiseaseBusiness Wire • 12/08/20
Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/07/20
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/06/20
Rocket Pharmaceuticals to Hold Webcast for Investors Highlighting Data Presented at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/02/20
Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant OsteopetrosisBusiness Wire • 11/13/20
Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 11/04/20
Rocket Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent ProgressBusiness Wire • 11/04/20
Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 MeetingBusiness Wire • 10/16/20
Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 MeetingBusiness Wire • 10/01/20
Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon DiseaseBusiness Wire • 09/02/20
Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant OsteopetrosisBusiness Wire • 08/27/20
Rocket Pharmaceuticals Expands Clinical Sites for its FA, Danon, LAD-I and IMO Trials, Adding to its Global Centers of ExcellenceBusiness Wire • 08/26/20
Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent ProgressBusiness Wire • 08/05/20